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Abstract Tumours require a vascular supply to grow and
can achieve this via the expression of pro-angiogenic
growth factors, including members of the vascular endo-
thelial growth factor (VEGF) family of ligands. Since one
or more of the VEGF ligand family is overexpressed in
most solid cancers, there was great optimism that inhibition
of the VEGF pathway would represent an effective anti-
angiogenic therapy for most tumour types. Encouragingly,
VEGF pathway targeted drugs such as bevacizumab, sun-
itinib and aflibercept have shown activity in certain set-
tings. However, inhibition of VEGF signalling is not
effective in all cancers, prompting the need to further
understand how the vasculature can be effectively targeted
in tumours. Here we present a succinct review of the pro-
gress with VEGF-targeted therapy and the unresolved
questions that exist in the field: including its use in dif-
ferent disease stages (metastatic, adjuvant, neoadjuvant),
interactions with chemotherapy, duration and scheduling of
therapy, potential predictive biomarkers and proposed
mechanisms of resistance, including paradoxical effects
such as enhanced tumour aggressiveness. In terms of future
directions, we discuss the need to delineate further the
complexities of tumour vascularisation if we are to develop
more effective and personalised anti-angiogenic therapies.
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Introduction
The concept of ‘anti-angiogenic therapy’ arose from the
seminal observations of Judah Folkman and colleagues.
Pre-clinical studies showed that tumours induce the
sprouting of new vessels from the surrounding vasculature
(sprouting angiogenesis) and that this process is vital for
the growth of tumours beyond 2–3 mm in size (Fig. 1). It
was therefore proposed that inhibition of sprouting angio-
genesis could suppress tumour growth in humans [1].
Further studies established that (a) vascular endothelial
growth factor-A (VEGF) is a key driver of sprouting
angiogenesis, (b) VEGF is overexpressed in most solid
cancers, and (c) inhibition of VEGF can suppress tumour
growth in animal models [2–4]. Based on these observa-
tions, numerous therapies have been developed that target
angiogenesis by blocking the VEGF signalling pathway
(Fig. 2). The biology of VEGF signalling, angiogenesis
and the principles upon which anti-angiogenic therapy is
based have been extensively reviewed [2, 5–8]. Here we
review the progress of VEGF-targeted therapies in the
clinic (see also Table 1), discuss the current questions and
controversies that exist in the field and propose routes to
more effective and personalised anti-angiogenic therapy.
Anti-angiogenic therapy in the metastatic setting
Since angiogenesis is deemed necessary for the growth of
metastases in all sites of the body, it is assumed that anti-
angiogenic therapy should be of benefit for patients with
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metastatic disease. However, variable results have been
obtained across different cancer types, suggesting that
whilst the metastases of certain cancers are sensitive to this
form of therapy, the metastases of others are not. Tyrosine
kinase inhibitors (TKIs), designed to inhibit VEGF recep-
tor signalling (Fig. 2), have demonstrated single-agent
activity in several indications. In metastatic renal cell
carcinoma (mRCC) these agents have proven highly suc-
cessful, with four drugs now FDA approved in this setting,
namely sorafenib, sunitinib, pazopanib and axitinib.
Sorafenib was the first TKI to demonstrate activity in
mRCC, in a placebo-controlled phase III randomised trial
of patients who had progressed on previous cytokine
therapy [9]. Progression free survival (PFS) was almost
doubled (5.5 vs. 2.8 months) and an improvement in
overall survival (OS) was observed when placebo-treated
patients crossing over to sorafenib were excluded from
the analysis [10]. A subsequent study comparing single
agent sunitinib with interferon-a in mRCC patients
(that were naı¨ve to treatment) demonstrated a significant
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Fig. 1 The role of sprouting angiogenesis in tumour growth. Early
observations on the growth of tumours supported the following model
for how tumours obtain a vascular supply. a When a tumour mass is
small, it can obtain oxygen and nutrients from existing local blood
vessels. b As the tumour grows beyond the capacity of local blood
vessels, soluble pro-angiogenic factors are released which promote
the sprouting of new vessels from local existing blood vessels
(sprouting angiogenesis). c These vessels provide a blood supply for
the tumour and this is required in order for the tumour to grow beyond
2–3 mm in size
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Fig. 2 VEGF-targeted agents. The VEGF signalling system in
mammals is complex and consists of five related ligands, VEGF-A,
VEGF-B, VEGF-C, VEGF-D and PLGF that bind with different
specificities to three receptor tyrosine kinases, VEGFR1, VEGFR2
and VEGFR3. The biology of these interactions has been extensively
reviewed [231, 233]. Shown is a highly simplified diagram designed
to illustrate the three major classes of agent that target this signalling
system: (a) ligand binding agents that block the binding of VEGF
ligands to receptors (e.g. bevacizumab which binds to VEGF-A alone
and aflibercept which binds to VEGF-A, VEGF-B and PLGF),
(b) antibodies that block signalling through VEGF receptors (e.g.
ramucirumab which binds to VEGFR2) and (c) tyrosine kinase
inhibitors which block the kinase activity of VEGFR1, VEGFR2 and
VEGFR3 (e.g. sorafenib, sunitinib, pazopanib). Note that these
tyrosine kinase inhibitors can also can inhibit the kinase activity of
some other receptor tyrosine kinases, including platelet derived
growth factor receptors (PDGFRs), c-Kit and fms-related tyrosine
kinase (FLT3) [233]
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Table 1 Randomised trials of anti-angiogenic agents cited in this article
Indication Treatment Trial identifier
and citation
Outcome
Breast cancer
Metastatic 1st line Paclitaxel ± bevacizumab E2100 [40] Improvement in PFS not OS
Docetaxel ± bevacizumab (HER-2 negative population) AVADO [41] Improvement in PFS, OS NA
Capecitabine, taxane or anthracycline ± bevacizumab
(HER-2 negative population)
RIBBON-1 [42] Improvement in PFS but not in OS
Docetaxel and trastuzumab ± bevacizumab (HER-2
positive population)
AVEREL [104] No improvement in PFS, OS NA
Docetaxel ± sunitinib (HER-2 negative population) Sun 1064 [45] No improvement in PFS or OS
Paclitaxel ± bevacizumab or sunitinib (HER-2 negative
population)
SUN 1094 [46] Inferior PFS for sunitinib arm
Metastatic 2nd line
and beyond
Capecitabine ± bevacizumab AVF2119 [39] No improvement in PFS or OS
Capecitabine, taxane, gemcitabine, or
vinorelbine ± bevacizumab (HER-2 negative
population)
RIBBON-2 [43] Improvement in PFS but not in OS
Capecitabine ± sunitinib NCT00435409
[44]
No improvement in PFS or OS
Capecitabine vs. sunitinib (HER-2 negative population) SUN 1107 [47] Inferior PFS and OS for sunitinib arm
Adjuvant Anthracycline, taxane or both ± bevacizumab
(triple negative population)
BEATRICE
[58]
No improvement in DFS, OS NA
Neo-adjuvant Doxorubicin/docetaxel/
cyclophosphamide ± bevacizumab
NCT00408408
[63]
Improvement in pathological complete
response rate (primary endpoint)
Epirubicin/docetaxel/Cyclophosphamide ± bevacizumab
(HER-2 negative population)
NCT00567554
[64]
Improvement in pathological complete
response rate (primary endpoint)
Colorectal cancer
Metastatic 1st line FOLFIRI ± bevacizumab AVF2107 [19] Improvement in OS and PFS
FOLFOX or XELOX ± bevacizumab NO16966 [21] Improvement in OS and PFS
Capecitabine ± bevacizumab AVEX [22] Improvement in PFS, OS NA
FOLFIRI ± sunitinib SUN1122 [28] No improvement in PFS
FOLFOX ± vatalanib CONFIRM 1
[29]
No improvement in PFS or OS
Metastatic 2nd line
and beyond
FOLFOX ± bevacizumab E3200 [20] Improvement in OS and PFS
FOLFOX ± vatalanib CONFIRM 2
[30]
Improvement in PFS but not OS
FOLFIRI ± aflibercept VELOUR [27] Improvement in OS and PFS
Regorafenib versus placebo CORRECT [31] Improvement in OS
Continuation
beyond
progression
Chemotherapy ± bevacizumab ML18 147 [92] Improvement in OS
Adjuvant FOLFOX ± bevacizumab NSABP C-08
[56]
No improvement in OS
FOLFOX or XELOX ± bevacizumab AVANT [57] No improvement in OS
Hepatocellular carcinoma
Metastatic 1st line Sorafenib versus placebo NCT00105443
[17]
Improvement in PFS and OS
Brivanib versus sorafenib BRISK-FL
[145]
OS non-inferiority end-point for brivanib
versus sorafenib not met
Metastatic 2nd line Brivanib versus placebo BRISK-PS
[146]
Improvement in PFS but not OS
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improvement in PFS in the sunitinib arm (11 vs.
5 months) [11]. Improvement in OS was observed in the
sunitinib arm (26.4 vs 21.8 months) and in a subset-ana-
lysis of patients who did not receive any post-study
cancer treatment, improvement in OS was even more
marked (28.1 vs. 14.1 months) [12]. Single agent pazop-
anib compared with placebo was subsequently shown to
extend PFS in mRCC in the first-line setting (11.1 vs.
2.8 months), but extensive crossover from placebo to
pazopanib confounded the final OS analysis [13, 14]. A
recent phase III trial comparing sunitinib with pazopanib
has demonstrated that both drugs have similar efficacy
[15] and single agent therapy with either drug is now
recommended as standard of care in the first-line in
mRCC. Axitinib, a more recently developed TKI, has
shown efficacy in the second-line setting in patients that
progressed on first-line TKI therapy [16] and is now
recommended for mRCC in this setting.
Table 1 continued
Indication Treatment Trial identifier
and citation
Outcome
Melanoma
Metastatic 1st line Paclitaxel/carboplatin ± bevacizumab BEAM*** [48] No improvement in PFS or OS
Paclitaxel/carboplatin ± sorafenib NCT00110019
[49]
No improvement in PFS or OS
Metastatic 2nd line Paclitaxel/carboplatin ± sorafenib NCT00111007
[50]
No improvement in PFS or OS
NSCLC*
Metastatic 1st line Paclitaxel/carboplatin ± bevacizumab NCT00021060
[32]
Improvement in PFS and OS
Cisplatin/gemcitabine ± bevacizumab AVAiL [33] Improvement in PFS but not OS
Ovarian cancer
Metastatic 1st line Paclitaxel/carboplatin ± bevacizumab ICON-7 [36] Improvement in PFS, OS NA
Paclitaxel/carboplatin ± bevacizumab GOG218 [37] Improvement in PFS, OS confounded by
cross-over
Metastatic 2nd line Gemcitabine/carboplatin ± bevacizumab OCEANS [38] Improvement in PFS but not OS
Pancreatic cancer
Metastatic 1st line Gemcitabine ± bevacizumab CALGB 80303
[51]
No improvement in PFS or OS
PNET
Metastatic 1st line Sunitinib versus placebo NCT00428597
[18]
Improvement in PFS, OS NA
Prostate cancer**
Metastatic 1st line Docetaxel/prednisone ± bevacizumab CALGB 90401
[52]
Improvement in PFS but not OS
Docetaxel/prednisone ± aflibercept VENICE [53] No improvement in PFS or OS
Renal cancer
Metastatic 1st line Sorafenib versus placebo TARGET [9] Improvement in PFS and OS
Sunitinib versus interferon-alpha NCT00098657
[11]
Improvement in PFS and OS
Pazopanib versus placebo NCT00334282
[13]
Improvement in PFS, OS confounded by
cross-over
Sunitinib versus pazopanib COMPARZ
[15]
PFS and OS were similar
Metastatic 2nd line Axitinib versus sorafenib AXIS [16] Improvement in favour of axitinib for PFS
but not OS
DFS disease-free survival, FOLFIRI 5-FU, leucovorin and irinotecan, FOLFOX 5-FU, leucovorin and oxaliplatin, HER-2 human epidermal
growth factor receptor-2, NA not available (pending, unknown or not reported), NSCLC non-small cell lung cancer, OS overall survival, PNET
pancreatic neuroendocrine tumour, PFS progression-free survival
* Non-squamous NSCLC only; ** castration resistant; *** randomised phase II study
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TKIs have also shown single agent activity in advanced
hepatocellular carcinoma and advanced pancreatic neuroen-
docrine tumours (PNET). In hepatocellular carcinoma, so-
rafenib improved OS from 7.9 to 10.7 months versus placebo
in a randomised phase III study, leading to its FDA approval in
2007 [17]. Sunitinib is FDA-approved for the treatment of
PNET based on the results of a randomised placebo-controlled
study that demonstrated doubling of PFS from 5.5 months in
the control arm to 11.4 months in the sunitinib arm, although
the OS analysis was confounded by cross-over of patients
from the control arm to the sunitinib arm [18].
Bevacizumab, a humanised monoclonal antibody that
binds specifically to VEGF-A alone, has shown efficacy in
several indications in the metastatic setting. The first phase
III trial published demonstrating the efficacy of an anti-
angiogenic agent in the clinic was in metastatic colorectal
cancer (mCRC), where the combination of chemotherapy
with bevacizumab was shown to result in superior PFS (10.6
vs. 6.2 months) and OS (23 vs. 15.3 months) compared to
the chemotherapy only arm [19]. Based on these data, bev-
acizumab was approved for the treatment of mCRC when
given in combination with chemotherapy. Subsequent phase
III studies have also demonstrated a beneficial effect of
adding bevacizumab to chemotherapy in mCRC [20–22].
Additional evidence for the efficacy of anti-angiogenic
therapy in colorectal cancer comes from a study of afliber-
cept, a novel fusion protein that binds to three VEGF family
ligands: VEGF-A, VEGF-B and placental growth factor
(PLGF). By targeting VEGF-B and PLGF, which are also
implicated in angiogenesis and/or the survival of newly
formed vessels, aflibercept may have additional anti-angio-
genic effects beyond targeting VEGF-A alone [23–26].
Adding aflibercept to chemotherapy was shown to extend
PFS and OS compared to chemotherapy alone in metastatic
colorectal cancer [27]. Moreover, a striking separation of the
survival curves was observed in this study, with 2-year sur-
vival significantly increased in the aflibercept arm compared
to the control arm (28.0 vs. 18.7 %) [27]. Based on these
data, aflibercept was recently approved for the treatment of
mCRC when given in combination with chemotherapy.
Curiously, despite the benefit observed when bevacizumab
or aflibercept are combined with chemotherapy in mCRC,
efforts to combine anti-angiogenic TKIs with chemotherapy
in mCRC have so far proven disappointing in terms of
improving OS [28–30]. However, single agent treatment with
the TKI regorafenib was recently reported to extend OS
compared to placebo in mCRC patients who had previously
progressed on standard therapies [31]. Regorafenib is now
approved for the treatment of mCRC in this setting.
In non-squamous non-small cell lung cancer (NSCLC),
two phase III trials have shown an improvement in PFS for
the addition of bevacizumab to chemotherapy [32–34]
although only one study reported an improvement in OS
[32]. A recent meta-analysis, combining data from these
two phase III studies (plus data from two phase II studies)
including [2,000 patients, concluded a small but signifi-
cant improvement in OS of 4 % at 1 year [35].
In the first-line treatment of ovarian cancer, two pivotal
studies (ICON-7 and GOG218) have been reported exam-
ining the addition of bevacizumab to chemotherapy [36,
37]. Both studies reported a significant improvement in
PFS of between 2.4 and 3.8 months. OS data were not
significant in the GOG218 study (but were confounded due
to cross-over) and OS data are still awaited for the ICON7
study. However, in ICON7, an improvement in overall
survival with bevacizumab was observed in the high-risk
group compared to chemotherapy alone (36.6 vs.
28.8 months). In relapsed ovarian cancer, the addition of
bevacizumab to chemotherapy has demonstrated a signifi-
cant improvement in PFS, although this has not translated
into an OS benefit [38].
In contrast to these promising data, there are several
notable examples of metastatic cancers where anti-angio-
genic agents have consistently failed to make a significant
impact on overall survival, including breast, melanoma,
pancreatic and prostate. The history of anti-angiogenic
therapy in the treatment of metastatic breast cancer is of
significant interest. In 2005, the AVF2119 phase III study
demonstrated that the addition of bevacizumab to cape-
citabine did not result in extension of either PFS or OS in
metastatic breast cancer [39]. However, in 2007, the E2100
phase III study demonstrated that the addition of bev-
acizumab to paclitaxel resulted in extension of PFS (11.8
vs. 5.9 months), but not OS, in metastatic breast cancer
[40]. On the basis of these data, the FDA granted the
accelerated approval of bevacizumab in combination with
paclitaxel for the treatment of HER2-negative metastatic
breast cancer. Three further phase III trials of bevacizumab
in combination with chemotherapy in HER2-negative
metastatic breast cancer (AVADO, RIBBON-1 and RIB-
BON-2) demonstrated an extension of PFS, but no effect
on OS, when compared to chemotherapy alone [41–43]. In
2010, the FDA concluded that the results of these studies
failed to provide evidence that bevacizumab could prolong
survival in metastatic breast cancer. As a consequence of
this, in 2010 the FDA withdrew its approval for bev-
acizumab in this indication. In addition to this, disap-
pointing results have also been observed with TKIs in
breast cancer. Three phase III studies examining the
addition of sunitinib to chemotherapy [44–46], and one
comparing single agent sunitinib versus chemotherapy
[47], all failed to demonstrate improvement in PFS or OS.
Studies in melanoma assessing the benefit of adding
either bevacizumab [48] or sorafenib [49, 50] to chemo-
therapy in the first- and/or second-line setting have all
failed to reach their primary efficacy end-point of PFS. In
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adenocarcinoma of the pancreas, the addition of bev-
acizumab to chemotherapy in a phase III randomised trial
failed to improve PFS [51]. In men with castrate-resistant
prostate cancer, the addition of bevacizumab [52], or af-
libercept [53], to chemotherapy have failed to improve OS
in comparison to chemotherapy alone.
The precise explanation as to why conventional anti-
angiogenic agents show efficacy in some metastatic can-
cers, and not others, is currently unknown [54]. Conceiv-
ably, important differences in the biology of these cancers
may underlie the contrasting results seen with this thera-
peutic approach across different cancers.
Anti-angiogenic therapy in the adjuvant setting
The use of anti-angiogenic agents in the adjuvant setting is
based on the principle that, after surgical removal of the
primary tumour, inhibition of angiogenesis may prevent
local relapse or the growth of micrometastatic tumours. Two
phase III trials in the adjuvant setting (NSABP C-08 and
AVANT) were designed to compare overall survival in
colorectal cancer patients treated with chemotherapy alone
for 6 months in one arm and chemotherapy plus bev-
acizumab for 6 months (followed by 6 months bevacizumab
maintenance therapy) in the second arm. In both trials, an
analysis performed after 1 year demonstrated improved PFS
in the bevacizumab arm. However, no significant difference
in OS was observed between treatment arms when assessed
at 3 or 5 years [55–57]. In addition to these data, recently
disclosed findings from the BEATRICE trial show that
adjuvant bevacizumab failed to improve disease free sur-
vival in triple negative breast cancer patients at 3 years [58].
Given the efficacy demonstrated for bevacizumab in
metastatic colorectal cancer, the poor results achieved in
the adjuvant setting are clearly disappointing. The results
suggest that, even in a disease where anti-angiogenic
therapy is shown to be effective in the metastatic setting,
the same may not be true when used in the adjuvant setting.
However, this situation is not unique to bevacizumab,
because it has been reported for other agents in colorectal
cancer. In colorectal cancer, for many years the quest for
successful adjuvant therapies has followed a simple and
reliable path. Drugs such as 5-FU, oxaliplatin and cape-
citabine were first shown to be effective in the metastatic
setting, which was followed by successful trials in the
adjuvant setting [59–61]. However, there are now three
notable exceptions that have not followed this path: irino-
tecan, cetuximab and bevacizumab have all shown efficacy
in the metastatic setting, but failed in the adjuvant setting in
colorectal cancer [56, 57, 59, 62]. The reasons that underlie
these discrepant results are currently unknown. However, it
seems most likely that the biology of micrometastases can
be very different to the biology of established metastatic
disease and that this has important consequences for ther-
apy response.
Anti-angiogenic therapy in the neoadjuvant setting
Theoretically, there may be several advantages to using
anti-angiogenic therapy in the neoadjuvant setting. Firstly,
it might be used to downsize a tumour in order to convert a
non-resectable lesion to one that is potentially resectable.
Secondly, it might be used to downstage the disease to
reduce the chance of local relapse or metastasis. Two large
randomised trials recently reported on the efficacy of
bevacizumab plus chemotherapy as a neoadjuvant therapy
for primary breast cancer compared to neoadjuvant che-
motherapy alone [63, 64]. Both used pathological complete
response (pCR) as the endpoint. Although a significant
increase in the rate of pCR was observed, the absolute
increase in response rate was small (3.5 and 6.3 %,
respectively). Moreover, subgroup analysis revealed con-
tradictory findings, with one study reporting greater benefit
in women with hormone receptor negative (triple negative)
disease [64] and the other study suggesting that women
with hormone receptor positive cancer were more likely to
benefit [63]. It is as yet unclear whether any survival
benefit will be associated with the use of bevacizumab in
this setting because there is currently no mature data.
In CRC, surgical resection of liver metastases is poten-
tially curative and has significantly improved overall sur-
vival in this setting [65]. Although only a fraction of patients
are resectable at presentation the use of neoadjuvant che-
motherapy to convert unresectable metastases to potentially
resectable metastases has lead to improvements in resection
rates and is a recommended practice [66]. Interestingly, there
is evidence to suggest that combination of bevacizumab with
chemotherapy may also be an effective conversion therapy
for CRC liver metastasis [67–69]. However, a randomised
trial directly comparing the efficacy of chemotherapy versus
chemotherapy combined with an anti-angiogenic agent has
not been undertaken in this setting.
Interactions with chemotherapy
In most settings, with the exception of ovarian cancer
where single agent activity for bevacizumab has been
observed [70], anti-angiogenic agents such as bevacizumab
and aflibercept have only shown significant activity when
they are combined with cytotoxic chemotherapy [19, 27].
How can this be explained? For some time, the prevailing
explanation for this effect has been the concept of ‘vascular
normalisation.’ Tumour vessels are known to be leaky and
476 Angiogenesis (2014) 17:471–494
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dysfunctional, leading to increased interstitial fluid pres-
sure, which may in turn impede the delivery of chemo-
therapy [71, 72]. Preclinical studies showed that
suppression of VEGF signalling can lead to improvements
in tumour vessel function (vascular normalisation), and in
turn, this was proposed to mediate increased delivery of
chemotherapy to tumours [71, 72]. Therefore, a widely
held conception is that bevacizumab ‘works’ in the clinic
because it improves the delivery of co-administered che-
motherapy. However, the clinical relevance of this phe-
nomenon for chemotherapy delivery in patients is still
unclear. For example, the addition of bevacizumab to
chemotherapy would be expected to lead to improvements
across the board in all settings, but this is not the case.
Moreover, a recent study reported the opposite relationship
i.e. bevacizumab led to a sustained decrease in the delivery
of chemotherapy in NSCLC patients [73].
At this point it should be noted that pharmacological
induction of vessel normalisation may have additional
therapeutic effects in cancer beyond control of chemo-
therapy delivery. For example, in glioblastoma patients,
vessel normalisation induced by VEGF-targeted therapy
may prolong survival due to alternative mechanisms
involving oedema control or improved tumour oxygena-
tion [74, 75]. Despite these facts, it is still not clear why
agents like bevacizumab and aflibercept show greater
activity when they are combined with chemotherapy. Any
number of alternative mechanisms could underlie this
activity. For example, an alternative explanation is that
anti-angiogenic drugs prevent the rebound in tumour
growth that may occur during breaks in chemotherapy [76]
or counteract the ability of chemotherapy to promote
tumour invasion [77]. Importantly, in contrast to bev-
acizumab, TKIs generally show single agent activity and
so any mechanistic explanation for the synergy between
VEGF-targeted agents and chemotherapy must account for
this unexplained dichotomy. A recent study, which
examined data from both clinical samples and preclinical
models, provided intriguing evidence that this dichotomy
may stem from intrinsic differences in the stromal com-
ponent of different cancers [78]. They provided evidence
that, in cancers that are more responsive to bevacizumab
when it is combined with chemotherapy (e.g. mCRC,
NSCLC), the vasculature has a stromal-vessel phenotype,
where the vessels are surrounded by a well-developed
stroma. In contrast, cancers that are responsive to single
agent TKIs (e.g. mRCC, PNET) have a tumour-vessel
phenotype, where the vessels sit closer to the tumour cells
without a well-developed intervening stromal component.
Although the molecular mechanisms were not uncovered,
these data do suggest that an interaction between multiple
stromal components influences the response to anti-
angiogenic therapy.
Therefore, our understanding of why TKIs work as
single agents and why VEGF-targeted agents synergise
with chemotherapy in patients is still incomplete. A further
unresolved question is whether certain types of chemo-
therapy may work better with bevacizumab than others.
Several on-going phase III studies in advanced breast
cancer will address the efficacy of bevacizumab when
combined with different chemotherapies or with other
targeted agents [79, 80]. However, further studies that
elaborate on the mechanistic basis for the interaction of
chemotherapy with VEGF-targeted therapies are urgently
needed.
Toxicity
It was assumed that because angiogenesis is a relatively
rare process in the adult, VEGF-targeted therapies would
be toxicity free. However, clinical experience reveals a
number of adverse events associated with these agents,
including hypertension, proteinuria, impaired wound heal-
ing, gastrointestinal perforation, haemorrhage, thrombosis,
reversible posterior leukoencephalopathy, cardiac toxicity
and endocrine dysfunction, which have been extensively
reviewed [81, 82]. Although some of these side effects can
be managed in a routine fashion, excessive toxicity may
necessitate the use of treatment breaks, dose reductions or
even treatment cessation, which may limit therapeutic
efficacy. However, it has also been proposed that certain
side effects could be used as a predictive biomarker for
efficacy. Several studies have demonstrated a link between
the development of hypertension and longer PFS/and or OS
in patients treated with anti-angiogenic agents [83–86]. It
has been suggested that, if this association can be validated
prospectively, then assessment of hypertension early in
treatment might be used to stratify patients likely to benefit
from anti-angiogenic therapy versus those that might be
transferred to an alternative therapy.
Duration and scheduling of therapy
Preclinical and clinical work shows that when VEGF-tar-
geted therapy is discontinued, the tumour vasculature can
become rapidly re-established [87, 88]. Conceivably, this
could lead to tumour re-growth when therapy is withdrawn.
Indeed, there are reports of tumour re-growth during
planned treatment breaks in anti-angiogenic therapy [89,
90]. These data suggest that prolonged use of VEGF-tar-
geted therapy may be necessary to achieve maximal ther-
apeutic benefit. In support of this, an observational study,
which analysed data from 1,445 patients treated with
bevacizumab, showed that continuation of bevacizumab
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treatment beyond progression was indeed associated with
greater benefit in terms of overall survival [91]. This
observation was recently validated prospectively in mCRC
in the ML18 147 trial [92].
Another interesting observation is that acquired resis-
tance to anti-angiogenic therapy may in some cases be a
transient phenomenon. Following the development of
resistance to one VEGF-targeted agent, mRCC patients
have been transferred to a second course of VEGF-targeted
therapy. Surprisingly, a proportion of these re-challenged
patients respond again to therapy [93–95]. Moreover, the
benefit that is achieved upon re-challenge can be propor-
tional to the length of time that elapses between therapy
[96]. These data suggest that resistance to VEGF-targeted
therapy can sometimes be a reversible phenomenon [97].
There are some interesting parallels between these data and
preclinical studies also showing that resistance to VEGF-
targeted therapy can be reversible [98, 99]. Based on these
data, it seems possible that the incorporation of strategic
treatment breaks might help to ‘reset’ tumour resistance
and avoid the onset of acquired resistance. However, this
idea has yet to be formally proved in the clinic.
Predictive biomarkers
Given the variable results obtained with anti-angiogenic
agents in the clinic, there is a need to distinguish which
patients are likely to benefit from this form of therapy from
those patients that will not. This entails the development of
predictive biomarkers that are capable of predicting
response or outcome [100–102]. However, despite inten-
sive efforts, there are currently no validated biomarkers for
selecting these patients. Many types of predictive bio-
markers have been investigated, including hypertension,
circulating markers, germline single nucleotide polymor-
phisms (SNPs), in situ markers in tumour material and
functional imaging. This area has been extensively
reviewed [101, 102] and we will cover here only some
recent developments in circulating markers, SNPs and
imaging.
Circulating markers
Historically speaking, studies examining baseline-circu-
lating levels of angiogenesis-related factors, such as VEGF,
have yielded disappointing and contradictory findings,
often providing prognostic rather than predictive informa-
tion [10, 101–103]. However, recent studies, based on
prospective, robust sample sets collected within clinical
trials are now starting to show more consistent results. For
example, a correlation between high circulating levels of
VEGF-A and survival benefit in metastatic breast and
gastric cancer patients treated with bevacizumab has been
reported [104–106]. A large phase III trial (MERiDIAN)
will prospectively test the utility of high circulating VEGF-
A levels as a potential biomarker of response to bev-
acizumab in HER2-negative metastatic breast cancer [105].
Biomarker signatures, composed of multiple circulating
factors, may also have potential value as predictive bio-
markers. In pazopanib-treated mRCC patients for example,
circulating levels of six serum cytokines and angiogenesis
factors (CAF) (HGF, interleukin 6, interleukin 8, osteo-
pontin, VEGF, and TIMP1) were able to identify a sub-set
of patients that derived significantly greater overall sur-
vival benefit from treatment [107]. Moreover, a serum-
based protein signature composed of mesothelin, FLT4,
AGP and CA125 has recently been shown to identify
patients with ovarian cancer more likely to benefit from
bevacizumab [108].
However, there are several challenges associated with
taking circulating factors forward as a prospective marker.
Firstly, measurement of circulating markers can be difficult
to standardise across centres, due to technical issues asso-
ciated with sample handling [109]. Secondly, deciding on a
predefined cut-off for high versus low levels of circulating
factors is challenging because it may vary with geography
and disease setting [109].
SNPs
Baseline predictive markers that are binary in nature (i.e. a
mutation or gene amplification) are attractive because they
may be easier to measure and apply prospectively than
biomarkers based on the measurement of circulating fac-
tors. A large study that examined data from two phase III
trials of bevacizumab in metastatic pancreatic adenocarci-
noma (AViTA) and mRCC (AVOREN) recently reported
that a SNP in VEGFR1 was significantly associated with
poor outcome in patients treated with bevacizumab [110].
The same SNP has subsequently been associated with poor
outcome in mRCC patients treated with sunitinib [111].
Fine mapping of this SNP to tyrosine 1,213 of VEGFR1
shows that mutation at this site leads to increased expres-
sion and signalling of VEGFR1, providing a plausible
explanation as to why VEGF-targeted therapy is less
effective in patients bearing this SNP [110]. Therefore, this
work identifies a negative biomarker that might be used
prospectively to exclude patients who are less likely to
benefit from VEGF-targeted therapy.
Imaging
Functional imaging of the tumour vasculature, using CT,
MRI or PET, is a potentially attractive approach for pre-
dicting response and outcome, as reviewed in [112].
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Imaging permits inspection of various parameters, such as
tumour morphology and blood flow, which may provide
important predictive information. There are studies show-
ing that baseline features of tumours, such as the level of
vascular perfusion, can predict response or outcome in
patients treated with anti-angiogenic agents. For example,
at least 4 published studies demonstrate that a high level of
vascular perfusion predicts for response or outcome in
mRCC patients treated with TKIs [113–116]. Early chan-
ges in vascular characteristics detected on imaging after the
initiation of therapy have also been shown to correlate with
response or outcome. For example, many studies per-
formed in mRCC patients treated with TKIs show that a
reduction in vascular perfusion on therapy provides extra
predictive information regarding response or outcome than
using criteria based on change in lesion size alone [112,
117–123]. Moreover, in patients with colorectal liver
metastases treated with bevacizumab and chemotherapy,
changes in tumour morphology on CT were shown to
associate more significantly with overall survival than the
use of RECIST criteria [124]. Although these studies
suggest a promising role for imaging as a predictive marker
in certain settings, many challenges remain. For example,
we have an incomplete understanding of how features
detected on imaging correlate with the underlying tumour
biology [112]. Also, methodologies used to assess imaging
biomarkers vary considerably between studies and require
standardisation for their prospective application across
multiple study centres [112].
Therefore, biomarkers that predict response or outcome
for VEGF-targeted therapy are emerging, but they require
further standardisation and validation before they are
incorporated into clinical practice.
Mechanisms of response and resistance to VEGF-
targeted therapy
Resistance to anti-angiogenic therapy is a prominent issue
that likely explains the variable results obtained in the
clinic with this approach. Resistance can broadly be clas-
sified into intrinsic resistance (where tumours fail to
respond from the outset of treatment) and acquired resis-
tance (where tumours initially respond and then progress
whilst still on treatment) [125]. Since anti-angiogenic
therapy targets tumour cells indirectly by acting on tumour
blood vessels, mechanisms that determine response and
resistance are likely to stem from a complex interaction
between tumour cells and stroma.
Insight into this tumour-stromal relationship in the set-
ting of intrinsic resistance can be gained from studies in
mRCC patients, which examined both change in tumour
blood flow and change in lesion size in clinically detectable
tumours upon treatment with single agent anti-angiogenic
therapy [121–123]. In some cases, a strong vascular
response may be observed, which is accompanied by sig-
nificant tumour shrinkage (Fig. 3a) [121–123]. Tumours
undergoing this type of response probably fulfil two
important conditions: (a) the growth and survival of the
vasculature is very sensitive to the agent, and (b) tumour
cell survival is highly dependent on the vascular supply. In
the second instance, despite a strong vascular response,
tumour growth is only stabilised (Fig. 3b) [121–123]. In
this scenario, tumour cells may be adapted to survive,
despite a reduction in vascular supply. In the third instance,
the targeted agent results in minimal or insignificant sup-
pression of the tumour vascular supply, resulting in stabi-
lisation of disease or tumour progression (Fig. 3c) [121–
123]. In this scenario, the growth and survival of the vas-
culature is apparently poorly sensitive to the agent.
Longitudinal assessment of mRCC patients treated with
these agents demonstrates that acquired resistance to ther-
apy can also arise following a period of initial disease
control [121–123]. Acquired resistance may conceivably
occur because the tumour finds alternative means to drive
tumour vascularisation which are insensitive to the therapy
(Fig 3d) or because tumour cells become adapted so that
they can grow despite the reduced vascular supply (Fig 3e)
[123]. Evidence for specific cellular and molecular mech-
anisms that may underlie intrinsic or acquired resistance to
anti-angiogenic therapy are discussed below.
Heterogeneity of tumour blood vessels
The tumour vasculature is heterogeneous with respect to its
response to anti-angiogenic therapy, with some vessels
being sensitive whilst others are resistant (Fig. 4a). In
preclinical studies, VEGF-targeted therapy suppresses the
growth of newly formed tumour vessels, but is less effec-
tive against more established tumour vasculature [125–
127]. The prevailing explanation is that nascent tumour
blood vessels are dependent on VEGF, but eventually lose
this dependence due to a process of ‘vessel maturation.’
Newly formed tumour vessels may mature via different
routes, leading to the formation of at least six different
types of tumour blood vessel, which vary in their sensi-
tivity to VEGF-targeted therapy [126]. One aspect of vessel
maturation is the recruitment of pericytes to tumour ves-
sels, mediated by platelet-derived growth factors (PDGFs).
It has been demonstrated that inhibition of PDGF-mediated
pericyte recruitment improves the efficacy of VEGF-tar-
geted therapy [128, 129]. Of interest, many clinically
approved anti-angiogenic TKIs are potent inhibitors of
both VEGF and PDGF receptors (e.g. sunitinib, sorafenib,
pazopanib) and may therefore target pericyte recruitment.
However, paradoxically, in xenograft models TKIs have
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been shown to result in either decreased or increased per-
icyte coverage, dependent on the study [130–133]. There-
fore, whilst mature tumour vessels may be resistant to
VEGF-targeted therapy, it is not currently clear how these
tumour vessels can be effectively targeted.
Alternative pro-angiogenic signalling pathways
Other pro-angiogenic signalling pathways can stimulate
blood vessel growth and blood vessel survival even when
the VEGF-pathway is blocked (Fig. 4b). Pre-clinical
studies have identified numerous candidates including
angiopoietins [129], Bv8; Bombina variagata peptide 8
[134], EGF; epidermal growth factor [135], the Delta-
Notch pathway [136], FGF1 and FGF2; fibroblast growth
factors 1 and 2 [137, 138], HGF; hepatocyte growth factor
[139], IL-8; interleukin 8, [140], PDGF-C; platelet derived
growth factor-C [141, 142] and PLGF; placental growth
factor [26]. Most of these studies also show that co-tar-
geting of VEGF and the candidate factor improves thera-
peutic response. Therefore, therapies that target signalling
by multiple pro-angiogenic growth factors may be neces-
sary to achieve efficient and durable suppression of tumour
angiogenesis and tumour growth. There is also clinical
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Fig. 3 Response and resistance
to anti-angiogenic therapy.
Tumours may respond initially
to anti-angiogenic therapy in
different ways. a Therapy
results in a strong vascular
response (a significant reduction
in the amount of perfused
tumour vessels) and significant
tumour shrinkage. b Therapy
results in a strong vascular
response, but only stabilisation
of disease is achieved.
c Therapy results in a poor
vascular response (minimal
reduction in the amount of
perfused tumour vessels) and
tumour stabilises or progresses.
d, e After a period of response,
acquired resistance can occur.
This may be due to the
activation of alternative
angiogenic pathways (d) or
because tumour cells adapt to
the lack of a vascular supply via
various potential mechanisms
(e)
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evidence showing that circulating levels of certain pro-
angiogenic factors, including FGF2, HGF, PLGF and SDF-
1a can become elevated in patients just prior to progression
on anti-angiogenic therapy, providing potential evidence
that these factors are indeed related to the development of
acquired resistance [143, 144].
However, the concept that these alternative growth
factor and cytokine signalling pathways mediate resistance
to anti-angiogenic therapy has yet to be truly validated
clinically. The majority of TKIs used to treat patients
(including brivanib, cediranib, dovitinib, sunitinib, sorafe-
nib, vatalanib and many others) are multitargeted in nature
and can suppress the signalling of multiple pro-angiogenic
signalling pathways, including VEGF, FGF and PDGF.
And yet, despite this, tumours have been shown to progress
through treatment with these agents in many indications,
including metastatic breast cancer [44–47], glioblastoma
[75], hepatocellular carcinoma [145, 146] and mRCC
[147]. This is in contrast to preclinical studies demon-
strating a role for alternative growth factor signalling
pathways and questions the relevance of alternative pro-
angiogenic growth factors in mediating resistance to anti-
angiogenic therapy in patients.
Infiltrating stromal cells
It is now well established that tumours are a community
composed of both transformed tumour cells and distinct
stromal cell types. These stromal cells include fibroblasts
and many different kinds of immune cell (such as lym-
phocytes, granulocytes and macrophages) as well as the
cells that make up the vasculature (endothelial cells and
pericytes). The roles played by these different stromal cell
types in tumour progression have been extensively
reviewed [148–153]. Importantly, the tumour stroma can
promote tumour progression and therapy resistance,
including resistance to anti-angiogenic therapies [154–
157]. Preclinical studies have demonstrated that infiltration
of tumours by various stromal cell types, including
immature myeloid cells [158, 159], endothelial progenitor
cells [160] or fibroblasts [141] can all mediate resistance to
VEGF-targeted agents in preclinical models (Fig. 4c).
Although the precise mechanisms through which these
cells mediate resistance to anti-angiogenic therapy is not
completely clear, they may promote the survival of tumour
vessels and/or tumour cells through the secretion of growth
factors such as BV8, in the case of immature myeloid cells
[134], or PDGF-C, in the case of fibroblasts [141]. Alter-
natively, there is evidence that immature myeloid cells and
endothelial progenitor cells may promote resistance to
therapy by physically incorporating into tumour vessels
[161–163].
Adaptation of tumour cells to conditions of stress
Inhibition of tumour vascularisation should reduce the
supply of oxygen and nutrients to tumours and slow tumour
growth. However, preclinical work shows that tumour cells
can be adapted to survive, even when the vascular supply is
significantly reduced. These survival mechanisms include a
reduced propensity for certain tumour cells to die under
conditions of stress and may be driven by genetic aberra-
tions such as loss of p53 function [164, 165]. Tumours
treated with anti-angiogenic agents may also adapt to sur-
vive under conditions of nutrient withdrawal and hypoxia,
by adapting their metabolism or through autophagy [130,
166–170]. Pre-adaptation or reactive adaptation to stress
may therefore play a key role in determining whether
tumours respond to VEGF-targeted therapies (Fig. 4d)
[169, 171].
Alternative mechanisms of tumour vascularisation
Despite a prevailing dogma that tumours utilise mainly
VEGF-dependent sprouting angiogenesis (Fig. 1), it is now
apparent that tumour vascularisation may occur via diverse
mechanisms, including intussusceptive microvascular
growth (IMG), glomeruloid angiogenesis, vasculogenic
mimicry, looping angiogenesis and vessel co-option [3,
172, 173]. IMG is a process that generates two new vessels
via the fission of an existing vessel (Fig. 4e). It has been
observed in human primary melanoma and glioblastoma
[174, 175]. Glomeruloid angiogenesis results in tight nests
of tumour vessels known as a glomeruloid bodies (Fig. 4e).
Glomeruloid bodies have been reported in a wide range of
malignancies, including glioblastoma, melanoma, breast,
endometrial and prostate cancer [176]. In vasculogenic
mimicry, tumour cells organise into vessel-like structures
that are perfused via connection to the host vasculature
(Fig. 4e). It has been reported in many human cancers,
including melanoma, breast, ovarian, prostate and sarcoma
[177]. Recent pre-clinical studies suggest that tumour stem
cells can directly differentiate into endothelial cells or
pericytes, which may be a mechanism for vasculogenic
mimicry [178–180]. In looping angiogenesis, vessels are
extracted from normal surrounding tissue by the action of
contractile myofibroblasts [181] (Fig. 4e). Although only
well-characterised in wound healing, tumours might con-
ceivably also utilise looping angiogenesis [181]. In vessel
co-option, tumours recruit existing local blood vessels as
they invade into surrounding host tissue (Fig. 4e). Analysis
of human cancers reveals vessel co-option in glioblastoma
[182, 183], adenocarcinoma of the lung [184, 185] cuta-
neous melanoma [186], lung metastases of breast and renal
cancer [187–189], liver metastases of colorectal and breast
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cancer [190, 191] and brain metastases of lung and breast
cancer [192].
Importantly, these alternative mechanisms of angio-
genesis may be VEGF-independent and therefore capable
of mediating tumour vascularisation despite VEGF-inhi-
bition. For example, intussusceptive microvascular growth
was demonstrated as a mechanism via which tumours can
escape the effects of TKIs in a preclinical model of
mammary carcinoma [193]. Moreover, preclinical and
clinical data show that tumours in the brain can become
more infiltrative when the VEGF pathway is inhibited,
which may facilitate vessel co-option [54, 182, 183, 194–
198]. However, despite these data, we have very little
understanding of the molecular mechanisms that control
these alternative mechanisms of tumour vascularisation.
Increased tumour aggressiveness
Some pre-clinical studies report that VEGF-targeted ther-
apy can promote increased tumour invasion and metastasis
(Fig. 3f) [196, 199–201]. Paez-ribes et al. [196] and
Sennino et al. [200] demonstrated in a genetically engi-
neered mouse model (GEMM) of PNET (RIPTag mice),
that pharmacological inhibition of the VEGF pathway
(VEGF receptor inhibitory antibody or sunitinib) sup-
pressed the growth of the primary tumour. However, the
treated tumours became more invasive and showed an
increased incidence of liver and lung metastasis, compared
to vehicle controls. Ebos et al. [202] demonstrated that
sunitinib can suppress tumour growth when breast cancer
or melanoma cells are implanted into the primary site (i.e.
mammary fat pad or skin, respectively). However,
administration of sunitinib either prior to, or after, resection
of the primary tumour increased the incidence of metastasis
and led to a shortening of overall survival, compared to
vehicle controls [202]. In the same study, treatment of mice
with sunitinib prior to, or after, intravenous injection of
tumour cells also promoted the growth of metastases and
shortened overall survival, compared to vehicle controls
[202]. These data imply that VEGF-targeted therapies
could accelerate tumour progression when used in the
metastatic, adjuvant or neoadjuvant setting.
Although these results are alarming, follow-up pre-
clinical studies from other laboratories challenge some of
these findings [130, 203, 204]. Chung et al. [204] treated
four different GEMMs with a VEGF inhibitory antibody
and failed to find any evidence that treatment increased the
incidence of metastasis. However, they did observe
increased invasion and metastasis in a GEMM of PNET
treated with sunitinib [204]. Two further studies examined
more closely the ability of sunitinib to accelerate metastasis
in mice. Both Welti et al. [130] and Singh et al. [203]
showed that administration of sunitinib to mice, prior to
intravenous injection of tumour cells, only promotes
metastasis when sunitinib is administered at very high
doses, but not when lower, clinically relevant doses are
utilised. In addition, Welti et al. [130] showed that
although sunitinib treatment is associated with a worse
prognosis in a model of metastatic breast cancer, sunitinib
treatment was able to prolong survival in a model of
metastatic renal cancer.
Is there evidence that anti-angiogenic therapy can pro-
mote tumour aggressiveness in patients? A retrospective
analysis of mRCC patients treated with sunitinib found no
evidence of accelerated tumour growth, suggesting that
sunitinib does not accelerate tumour growth in advanced
renal cancer [205]. However, there are some reports of
rapid tumour progression in individuals with mRCC after
withdrawing anti-angiogenic therapy, a phenomenon
sometimes referred to as ‘flare-up’ [54, 89, 90, 206]. It has
been shown that, upon withdrawal of anti-angiogenic
therapy, the tumour vasculature can rapidly re-grow [87,
88]. Moreover, a recent neoadjuvant study of sunitinib and
pazopanib in mRCC demonstrated a paradoxical increase
in Ki67 and tumour grade in the primary tumour after
treatment [207]. These findings might provide some clues
to the source of the flare-up phenomenon, but the precise
mechanisms are as yet unclear.
The influence of bevacizumab treatment withdrawal has
also been assessed in patients. A retrospective analysis of
five large studies (which included patients with mRCC,
metastatic pancreatic cancer, metastatic breast cancer and
metastatic colorectal cancer) found no evidence that dis-
continuation of bevacizumab treatment lead to accelerated
bFig. 4 Potential mechanisms involved in resistance to VEGF-
targeted therapy. a Tumours present with a mixture of therapy-
sensitive and therapy-insensitive vessels. The top vessel is destroyed
by the therapy (depicted in grey), whilst the bottom one remains
(depicted in red). b Alternative signalling pathways can regulate the
sensitivity of vessels to therapy. In the panel, the tumour cells (in
blue) have up-regulated an alternative pro-angiogenic growth factor
in order to drive blood vessel growth and survival. c Stromal cells,
such as immature myeloid cells (black) or fibroblasts (green) infiltrate
the tumour and mediate resistance either by releasing pro-angiogenic
growth factors or by physically incorporating into vessels. d Tumour
cells can survive conditions of stress. Some tumour cells (depicted in
blue) have survived the loss of a vascular supply, because they are
adapted to survive conditions of hypoxia or nutrient shortage.
e Tumours may use alternative mechanisms of vascularisation besides
sprouting angiogenesis. In intussusceptive microvascular growth new
vessels are generated by the fission of existing vessels. Glomeruloid
angiogenesis is characterised by tight nests of vessels that resmemble
the renal glomerulus. In vasculogenic mimicry, tumour cells directly
form vascular channels (blue cells) that are perfused via connection to
the host vasculature (red cells). In looping angiogenesis, contractile
myofibroblasts (green) pull host vessels out of the normal surrounding
tissue (pink region). In vessel co-option tumour cells engulf host
vessels in the normal surrounding tissue (pink region) as the tumour
invades. f Increased tumour aggressiveness i.e. therapy causes tumour
to become more invasive and/or accelerates the growth of metastases
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disease progression compared to placebo controls [208].
Some data examining this question in the adjuvant setting
are also available. Analysis of the NSABP-C08 trial of
adjuvant bevacizumab in colorectal cancer failed to pro-
vide evidence for a detrimental effect of exposure to bev-
acizumab [56]. However, data from the AVANT trial of
adjuvant bevacizumab in colorectal cancer did find evi-
dence that treatment with bevacizumab was associated with
a detrimental effect: a higher incidence of relapses and
deaths due to disease progression was observed in the
bevacizumab treated patients [57]. It has been proposed
that the disappointing results obtained in the adjuvant set-
ting with bevacizumab could be explained by an adverse
effect of bevacizumab on tumour biology: increased
aggressiveness of the cancer [54].
There is one setting in which the induction of a more
invasive tumour phenotype upon treatment with anti-
angiogenic therapy is relatively undisputed. Glioblastomas
have been observed to adopt a more infiltrative tumour
growth pattern upon treatment with VEGF-targeted therapy
[182, 183, 209]. Interestingly, it seems plausible that this
invasive process can contribute to resistance to anti-angio-
genic therapy by allowing vessel co-option to occur [195].
In conclusion, there is conflicting evidence for the rel-
evance of increased tumour aggressiveness in response to
anti-angiogenic therapy and this persists as a controversial
area [54, 210, 211]. However, taken together, the available
data suggest that the ability of VEGF-pathway targeted
agents to promote tumour aggressiveness is influenced by
several factors, including cancer type, the stage of disease
being treated (neoadjuvant, adjuvant or metastatic) the
nature of the anti-angiogenic agent administered, the dose
of agent that the recipient is exposed to and the physiology
of the individual patient.
The mechanisms that underlie the increased invasiveness
and increased metastasis observed in some studies of VEGF-
targeted therapy are the subject of ongoing investigation.
Several studies have demonstrated that VEGF-targeted
therapy can cause tumour cells to undergo an epithelial-to-
mesenchymal transition, which could promote increased
invasion and metastasis [200, 201, 212, 213]. Activation of
the MET receptor has been implicated in the process of
increased invasion and metastasis observed upon VEGF-
targeted therapy in preclinical models, and simultaneous
inhibition of VEGF and MET signalling was shown to sup-
press the increased invasion and metastasis observed in
preclinical models of PNET and glioblastoma [199–201].
Another possible causative factor in the enhanced
metastasis observed in angiogenesis inhibitor treated mice
is a drug-induced change in circulating factors. For
example, it has been shown that TKIs in particular can
induce a significant change in a number of circulating
factors implicated in tumour progression including G-CSF,
SDF-1a and osteopontin [214]. A change in levels of these
factors could potentially contribute to tumour progression
at distant sites. In support of this concept, a recent study
showed that changes in circulating levels of interleukin-
12b were required for the enhanced metastasis observed
upon sorafenib treatment in a preclinical model of hepa-
tocellular carcinoma [215].
It is known that the integrity of the vasculature is
important in controlling metastasis [216, 217]. Therefore,
another possible mechanism could be that VEGF-targeted
therapies damage the vasculature, leading to enhanced
tumour cell extravasation at the primary site or increased
seeding at the metastatic site. There is some direct evidence
in preclinical models that TKIs may promote metastasis by
damaging the integrity of the vasculature [130, 199, 204].
Despite these data, more work is required to understand
in which settings increased aggressiveness may be relevant
and how it occurs at the mechanistic level. It remains to be
seen whether combination strategies designed to inhibit
both angiogenesis and invasion/metastasis will be neces-
sary to achieve a better therapeutic index in patients.
Signalling by VEGF in different cell types
Beyond its role in stimulating angiogenesis in endothelial
cells, it is now apparent that VEGF can play a signalling
role in many other cell types. These include: endothelial
cells of the normal vasculature [218], dendritic cells [219],
myeloid cells [220], neurons [221], pericytes [222] and
tumour cells [201, 212, 223–228]. Identification of these
additional physiological and pathophysiological roles for
VEGF has led to some surprising observations. For
example, inhibition of VEGF in the normal vasculature
may be the cause of certain side effects seen in patients
treated with VEGF-targeted agents, such as hypertension
[81], whilst suppression of VEGF signalling in myeloid
cells was shown to accelerate tumourigenesis in mice
[220]. This latter phenomenon may be another mechanism
leading to increased aggressiveness in cancers treated with
anti-angiogenic therapy.
In addition, there are numerous studies documenting a
role for VEGF signalling in tumour cells, but the data are
conflicting. Several studies have shown that cancer cell
lines can express VEGFR1 or VEGFR2 and that signalling
through these receptors in cancer cells can promote events
associated with tumour progression, including cancer cell
survival, proliferation, invasion or metastasis [224–229].
Based on these data it has been proposed that inhibition of
VEGF signalling in tumour cells may, at least in part, be
mediated by direct activity against tumour cells [4]. In
contrast, more recent preclinical studies have shown that
inhibition of VEGF signalling in CRC and glioblastoma
cells made these cells more invasive [201, 212]. These
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latter data suggest that, in fact, targeting VEGF signalling
in cancer cells may actually be deleterious. Further studies
are warranted to untangle this dichotomy.
Interactions between VEGF receptors and other cell
surface receptors
The VEGF signalling system in mammals is complex and
consists of five related ligands, VEGF-A, VEGF-B, VEGF-
C, VEGF-D and PLGF that bind with different specificities
to three receptor tyrosine kinases, VEGFR1, VEGFR2 and
VEGFR3. In addition, several co-receptors have been
identified, including heparin sulphate proteoglycans, neu-
ropilin 1 (NRP1), neuropilin 2 and CD146. Moreover,
VEGF receptors can cross-talk with additional cell surface
molecules, including integrins and other growth factor
receptors. The biology of this complex signalling system
has been extensively reviewed [8, 230–232]. Here we will
focus on some selected studies that examined the relevance
of these interactions in determining response or resistance
to VEGF-targeted therapies in cancer.
PLGF is overexpressed in many cancers and signals by
binding to VEGFR1 [233]. Combined inhibition of VEGF
and PLGF was shown to be more effective at suppressing
primary tumour growth than VEGF inhibition alone in
several preclinical models [26, 234]. However, these
results were challenged in a publication showing that,
although inhibition of PLGF can suppress metastatic
spread, it had no effect on the growth of primary tumours
[235]. Co-receptors for VEGFR2, including NRP1 and
CD146, may act to amplify signal transduction through
VEGFR2, leading to an increased angiogenic response
[233]. Combined inhibition of NRP1 and VEGF [236], or
CD146 and VEGF [237], were both shown to be more
effective than inhibition of VEGF alone in preclinical
primary tumour models.
VEGFR2 can also form direct complexes with other
receptor tyrosine kinases. For example, stimulation of
vascular smooth muscle cells with VEGF promotes the
formation of a complex between VEGFR2 and the receptor
tyrosine kinase PDGF-Rb [222]. This results in suppression
of PDGF-Rb signalling and decreased pericyte coverage in
tumours [222] and may explain the observation that, in
some experimental systems, inhibition of VEGF signalling
leads to increased pericyte coverage of tumour vessels and
increased maturation/normalisation of the tumour vascu-
lature [238]. Moreover, in glioblastoma cells, VEGF
stimulates the formation of a complex between VEGFR2
and the receptor tyrosine kinase, MET, which results in
suppression of MET signalling and reduced tumour cell
invasion [201]. As a consequence of this, inhibition of
VEGF was shown to release MET from this inhibitory
mechanism and allow for increased tumour invasion [201].
Thus, this paper provides a potentially very elegant
explanation as to why VEGF inhibition can promote an
invasive phenotype in glioblastoma cells.
Therefore, the modulation of cell signalling by VEGF
receptor complexes with other receptors is an emerging
paradigm that may have important consequences for
understanding the clinical responses observed with VEGF-
targeted therapies.
Future directions for anti-angiogenic therapy
Clinical experience provides proof-of-principle that anti-
angiogenic therapy is a valid therapeutic approach. The full
potential of this strategy is, however, yet to be realised. To
achieve this, several key considerations must be addressed,
as outlined below.
Understanding the vascular biology of different primary
cancers and their metastases
We may need to move beyond the belief that all cancers
vascularise via the same mechanism. Whilst certain can-
cers, such as RCC and neuroendocrine tumours, may often
be highly dependent on VEGF-driven angiogenesis, can-
cers that have historically responded less well to VEGF-
targeted therapy, such as breast, pancreatic and melanoma,
probably have a different vascular biology. Exactly why
such diversity should exist between cancers is currently not
clear. Tumour evolution is most likely an important factor.
For example, given that inactivation of the Von Hippel-
Lindau (VHL) gene is a frequent early event in renal cancer
that results in elevated expression of VEGF [239], it is
perhaps not surprising that the aetiology of these tumours is
strongly coupled with a dependence on VEGF-driven
angiogenesis. However, in other cancers where VHL
inactivation is not prevalent, VEGF-driven angiogenesis
may be just one of several tumour vascularisation pathways
that the cancer can evolve to utilise. Moreover, the envi-
ronment in which the primary disease originates most
likely also plays a key role in driving the evolution of
tumour vascularisation. The vasculature is not a homoge-
nous entity: considerable heterogeneity of form and func-
tion is observed between different organs [240]. As
different types of primary tumours evolve in different
organs (e.g. brain, breast, colon, skin, kidney, liver, lung,
pancreas, etc.) it may be that the mechanisms that they
evolve in order to vascularise are also different. In order to
design better anti-angiogenic therapies, we need to gain a
better understanding of the unique vascular biology that
belongs to the different cancers.
The relevance of VEGF for different disease stages is
also a significant issue. For example, whilst efficacy for
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anti-angiogenic therapy in the metastatic setting has been
shown for several indications, efficacy in the adjuvant
setting has yet to be demonstrated. Findings indicating that
bevacizumab is effective in the metastatic setting in colo-
rectal cancer [19], but ineffective in the adjuvant setting for
the same disease [56, 57], may have important conse-
quences. Many trials of anti-angiogenic agents in the
adjuvant setting are currently underway. Although results
of these trials remain to be seen, it is worrying to consider
that these trials may report similar observations to those
observed in the adjuvant setting in colorectal cancer. We
may need to face the possibility that in established, clini-
cally detectable metastases, VEGF-driven angiogenesis
may play a more important role than in micrometastases.
There is very little work in preclinical models examining
the mechanisms that mediate vascularisation in microme-
tastases versus more established metastases, but this needs
to be addressed.
Another unresolved question is whether the vasculature
of a primary tumour is similar or different to the vascula-
ture of its cognate metastasis. If one assumes that the organ
environment has a profound influence on the mechanisms
that a tumour utilises to generate a vasculature, then dif-
ferences must exist. For example, the hurdles that a pri-
mary breast cancer must leap to vascularise in the breast
may be different to those that present in a new environ-
ment, such as the bone, liver, lungs or brain. In support of
this, the colonisation of new organ environments during
metastasis is thought to be inefficient [241]. One reason for
this may be that tumours must ‘re-educate’ in order to
vascularise in the new environment. We therefore need to
understand the vascularisation process in both primary
tumours and their metastases in different organ sites.
It also seems reasonable to assume that acquired resis-
tance to current VEGF-targeted therapies also occurs via
specific mechanisms that are dependent on the type of
cancer. For example, new vessel growth driven by alter-
native pro-angiogenic growth factors, such as FGF2, HGF
or IL-8, may drive acquired resistance to TKIs in RCC or
neuroendocrine tumours [137, 138, 140, 144]. Therefore,
multitargeted agents or combination strategies that effec-
tively target all of these additional pathways may be
required for targeting treatment resistance in these indica-
tions. In contrast, acquired resistance in glioblastoma may
occur due to increased tumour invasion and vessel co-
option [182, 183, 195, 198, 201]. Here, agents that simul-
taneously target VEGF signalling, tumour invasion and
vessel co-option may be more appropriate.
The role of tumour heterogeneity
In patients with multiple metastases, a heterogeneous
response to anti-angiogenic therapy can sometimes be
observed i.e. some lesions may respond whilst other lesions
in the same patient can progress [123]. This is challenging
for optimal patient management and continuation of ther-
apy, and may herald early treatment failure. Although the
source of this heterogeneity is poorly understood, one
explanation could be that diverse tumour vascular biology
can exist in a patient. For example, histopathological
studies on human lung and liver demonstrate that tumours
present in these sites display significant intra- and inter-
tumour heterogeneity, utilising either angiogenesis or
vessel co-option to gain access to a vascular supply [173,
184, 185, 187, 190, 191, 242, 243]. This suggests that,
within the same tumour and between different tumours in
the same patient, more than one mechanism to become
vascularised can be utilised at any particular time. More-
over, comprehensive genomic analysis of tumours reveals
significant genetic intra- and inter-tumour heterogeneity
[244]. Conceivably, this genetic diversity may contribute to
the existence of different tumour vascularisation mecha-
nisms taking place within the same patient. Understanding
how this heterogeneity occurs and how to target it effec-
tively is a key goal, not just for anti-angiogenic therapy, but
for all cancer therapeutics [244, 245].
Preclinical experiments that translate to clinic
There is a prominent disconnect between the types of
preclinical models used to test the efficacy of anti-angio-
genic agents and the clinical scenarios in which these drugs
are utilised [54]. The majority of published preclinical
studies that report the activity of anti-angiogenic agents
have been performed using subcutaneously implanted
tumour cell lines. Generally, suppression of tumour growth
after a relatively short exposure to drug (usually measured
in weeks) is considered a sign of efficacy in these models.
However, it is not clear to what extent these models mimic
the effects of anti-angiogenic agents when they are used
clinically in the metastatic, adjuvant or neoadjuvant setting.
Moreover, very few studies use survival as an endpoint. In
support of the need for refined models, recent preclinical
studies clearly demonstrated that whilst anti-angiogenic
therapies can be effective at controlling tumour growth in
models of the primary disease, the same therapies were not
effective in models of the adjuvant or metastatic treatment
setting [202, 246]. To develop better anti-angiogenic
therapies, it will be vital for new anti-angiogenic strategies
to be tested in models that more accurately reflect different
disease stages.
In addition, there are a growing number of studies dem-
onstrating that resistance to VEGF-targeted agents might be
overcome by targeting a second pathway. This includes
targeting additional pro-angiogenic signalling pathways [26,
137–141, 236, 237, 247, 248] or by targeting compensatory
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metabolic or pro-invasive responses in tumour cells [166,
168, 170, 200, 201]. These studies are vital and should allow
the design of rationale combination strategies that could be
tested in the clinic. However, there are several practical
problems associated with this, including finding targets that
are easily druggable and selecting combinations that have an
acceptable toxicity profile [249]. A consideration of these
practicalities at the preclinical phase may accelerate the
selection of new strategies that can be practically and rapidly
translated to the clinic.
Development of appropriate predictive biomarkers
As we have seen, the biology determining response and
resistance to anti-angiogenic therapy is complex. It is
perhaps therefore unsurprising that predictive biomarkers
for this class of agent remain elusive. To identify which
patients will benefit from these therapies, mechanism-dri-
ven biomarkers are required that can account for the
dynamic and complex underlying biology. Importantly, as
more and more promising biomarkers are uncovered, a
further challenge will be to standardise methods of bio-
marker assessment across centres so that they can be val-
idated prospectively and, eventually, utilised routinely.
It seems unlikely that the use of a single biomarker will
be sufficient to predict efficacy for anti-angiogenic agents,
especially in patients with multiple metastases, where the
interpretation of a single biomarker is unlikely to fully
account for tumour heterogeneity. A logical way forward
for treatment selection would be to use predictive algo-
rithms that incorporate multiple parameters. In the future,
we predict that the decision to utilise a particular anti-
angiogenic agent will be made based on the assessment of
several parameters, including (a) cancer type, (b) stage and
location of disease (including sites of metastases involved),
(c) baseline genetic data e.g. germline SNPs, (d) circulating
markers acquired at baseline and during therapy, and
(e) functional imaging data acquired both at baseline and
during therapy. Moreover, in a world where multiple tar-
geted agents are now potentially available for tailored
treatment, the decision to use anti-angiogenic therapy will
need to be weighed against the use of other potentially
effective treatment options for each patient.
Alternative approaches for targeting the tumour
vasculature
Although the conventional concept of anti-angiogenic
therapy is to inhibit tumour blood vessel formation, there
may be other ways in which the vascular biology of
tumours could be targeted. Of course, one long-standing
hypothesis is that therapies should be designed to
normalise the tumour vasculature in order to improve the
delivery of chemotherapy [71, 72, 238]. This might be
particularly pertinent in poorly vascularised cancers such
as pancreatic adenocarcinoma where improved delivery of
chemotherapy could be beneficial [250]. Moreover, vas-
cular normalisation may have additional beneficial effects
for controlling oedema or tumour oxygenation [74, 75]. In
addition, it is now known that blood vessels are not merely
passive conduits for the delivery of oxygen and nutrients.
Beyond this, they can secrete specific ‘angiocrine factors’
that can control embryonic development, tissue regenera-
tion and tumour growth in a perfusion-independent manner
[251]. Furthermore, two recent studies showed that endo-
thelial cells can secrete specific ligands that induce che-
moresistance in tumour cells [252, 253]. These studies
reflect a growing paradigm that the tumour stroma plays an
important role in therapy resistance [150, 154, 156, 157].
Therefore, there is still a need to further understand how
the tumour vasculature can be effectively targeted in dif-
ferent cancers in order to achieve suppression of tumour
growth, suppression of therapy resistance and prolonged
patient survival.
Conclusions
Here we have reviewed progress in the field of VEGF-
targeted therapy and outlined some of the major unresolved
questions and challenges in this field. Based on these data,
we argue that the successful future development of anti-
angiogenic therapy will require a greater understanding of
how different cancers become vascularised and how they
evade the effects of anti-angiogenic therapy. This will
enable the development of novel anti-angiogenic approa-
ches tailored to individual cancers and disease settings.
Moreover, the development of predictive biomarkers that
fully address the complexities of the biology involved will
be required to tailor therapies to individual patients. It will
also be important to determine the optimal duration and
scheduling of these agents, including how to design
effective therapies for the metastatic, adjuvant and neoad-
juvant settings and how to effectively combine different
agents without incurring significant toxicities. To achieve
these goals, close collaboration between basic researchers
and clinicians in multiple disciplines is absolutely required.
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